<DOC>
	<DOC>NCT02682420</DOC>
	<brief_summary>Prospective, multi-center study to evaluate the everlinQ endoAVF System when used to create an endovascular arteriovenous fistula (endoAVF) for patients who require vascular access for hemodialysis.</brief_summary>
	<brief_title>everlinQ endoAVF Europe (EU) Study</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<criteria>Adult (age &gt;18 years old) Established, nonreversible kidney failure requiring hemodialysis (stage 4 or 5 renal disease) including predialysis patients Both radial and ulnar artery flow to the hand Known central venous stenosis or central vein narrowing &gt; 50% Occlusion or stenosis &gt;50% of target cannulation cephalic or basilic vein Significantly compromised (≥50% stenosis) flow in the treatment arm Documented ejection fraction (EF) ≤35% in the last 6 months Pregnant women New York Heart Association (NYHA) class III or IV heart failure Hypercoagulable state Known bleeding diathesis Known allergy to contrast dye which cannot be adequately premedicated Known adverse effects to sedation and/or anesthesia which cannot be adequately premedicated</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>